Abstract
Objective . Estimation of the effectiveness of low power brachytherapy sources I-125 in the combined treatment in group of patients of intermediate risk of localized prostate cancer. Material and methods. The study included 126 patients with prostate cancer of intermediate risk. 104 patients (83,9%) were conducted low power brachytherapy I‑125 in combination with hormone therapy by analogues of LHWG. 22 patients (16.1%) received external beam irradiation in combination with brachytherapy I‑125 and hormonal treatment. Relapse-free survival of patients was evaluated in accordance with the criteria Phoenix (Nadir PSA + ng/ml). Evaluation of side effects of radiation treatment were carried out according to the RTOG criteria. Results. PSA relapse-free survival in the group of brachytherapy and hormone treatment at the time of observation 5 years amounted to 97.1%. In the group of combined radiation therapy with brachytherapy, and hormonal treatment PSA relapse-free survival rate was 95.5%.In both groups, relapse-free survival was noted in 96,8% of cases. Tumor-specific and overall survival in both groups was 100%. The major complications of treatment in both groups were radiation urethritis 1 to 2 degrees in 9.5% of cases (12 patients), urethral stricture in 5 patients (3.9% of cases), acute urinary retention in 1 patient (0.8% of cases) and late radiation rectitis of 2 degree in 1.58% of cases (2 patients). Conclusions. It is possible to draw tentative conclusions about the high rate of survival without progression in both treatment groups on the background of the relatively low frequency of adverse reactions. It is necessary further follow-up for patients with estimating of survival for a longer period.
Highlights
Материалы и методы Специалистами Медицинского Радиологического Научного Центра г
Estimation of the effectiveness of low power brachytherapy sources I-125 in the combined treatment in group of patients of intermediate risk of localized prostate cancer
PSA relapse-free survival in the group of brachytherapy and hormone treatment at the time of observation 5 years amounted to 97.1%
Summary
Ключевые слова: рак предстательной железы, контактная лучевая терапия, брахитерапия I‐125, сочетанная лучевая терапия, гормональное лечение. Оценка эффективности низкомощностной брахитерапии источниками I‐125 в комбинированном лечении группы пациентов промежуточного риска локализованного рака предстательной железы. ПСА безрецидивная выживаемость в группе брахитерапии и гормонального лечения на срок наблюдения 5 лет составила 97,1%. В группе сочетанной лучевой терапии с брахитерапией и гормональным лечением ПСА безрецидивная выживаемость составила 95,5%.В обеих группах безрецидивная выживаемость отмечена в 96,8% случаев. Опухолево‐специфическая и общая выживаемость в обеих группах составила 100% Основными осложнениями проводимого лечения в обеих группах являлись лучевой уретрит 1–2 степени в 9,5% случаев (12 пациентов), стриктура уретры у 5 больных (3,9% случаев), острая задержка мочи у 1 пациента (0,8% случаев) и поздний лучевой ректит 2 степени в 1,58% случаев (2 больных). Можно сделать предварительные выводы о высоких показателях выживаемости без прогрессирования в обеих группах лечения на фоне сравнительно невысокой частоты побочных реакций. Biryukov V.A.1,Karyakin О.B.1, Morov О.V.2, LepilinaО.G.1, Neledov D.V.1, Sanin D.B1, Grishin G.N.1, Kalinina М.S.1
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
